Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Neumora Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for neuropsychiatric and neurological disorders, including major depressive disorder, schizophrenia, and other conditions with significant unmet medical need. The company operates within the biotechnology and pharmaceutical industries, with a strategic emphasis on precision neuroscience enabled by human genetics and translational science.
The company’s primary value drivers are its proprietary clinical and preclinical drug candidates targeting validated neurological pathways, supported by an integrated platform that combines genetics, neuroscience, and drug discovery. Neumora was founded in 2019 and incubated with support from Amgen, evolving from a research-focused organization into a publicly traded company following its initial public offering in 2023, which expanded its capital base and clinical development capabilities.
Business Operations
Neumora’s operations are organized around the research, development, and advancement of central nervous system (CNS) therapeutics, with revenue currently derived from financing activities rather than product sales, as no therapies have yet received regulatory approval. The company’s leading clinical programs include navacaprant (NMRA‑140), a kappa opioid receptor antagonist evaluated for major depressive disorder and anhedonia, and NMRA‑511, a selective muscarinic M4 positive allosteric modulator being studied for schizophrenia.
Operations are primarily based in the United States, with research and development activities supported by internal laboratories and external contract research organizations. Neumora controls its core intellectual property portfolio and development assets, and it has historically benefited from foundational research contributions and option-based collaboration frameworks originating from Amgen, though the company now operates independently.
Strategic Position & Investments
Neumora’s strategy centers on advancing a diversified neuroscience pipeline through mid- and late-stage clinical development while leveraging human genetic validation to improve probability of success. Growth initiatives focus on progressing lead assets through clinical milestones, expanding indications for existing compounds, and advancing earlier-stage programs toward investigational new drug filings.
The company has made substantial investments in its internal discovery platform and clinical infrastructure rather than pursuing large-scale acquisitions. Its pipeline reflects involvement in emerging neuroscience targets, including novel approaches to mood and psychotic disorders that differentiate Neumora from traditional monoamine-based therapies. Data regarding additional acquisitions or equity investments is inconclusive based on available public sources.
Geographic Footprint
Neumora Therapeutics is headquartered in South San Francisco, California, within a major U.S. biotechnology hub. Its operational footprint is primarily concentrated in North America, where research, development, and corporate functions are based.
While the company does not maintain extensive owned international facilities, its clinical trials and development programs have a global reach, utilizing study sites across multiple regions to support regulatory requirements and patient enrollment. This approach provides international exposure without significant fixed overseas infrastructure.
Leadership & Governance
Neumora is led by an executive team with experience across biotechnology, neuroscience research, and large pharmaceutical organizations. The leadership emphasizes a strategy grounded in scientific rigor, genetics-informed target selection, and disciplined clinical execution to address complex CNS disorders.
Key executives include:
- Robert L. Blum – Chief Executive Officer
- Michael J. Stroud – Chief Financial Officer
- Kari L. Olson – Chief Medical Officer
- Andrew Miller – Chief Scientific Officer
Information regarding founders and certain governance roles reflects disclosures in public filings; where inconsistencies exist across sources, data is inconclusive based on available public sources.